

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification<sup>6</sup> :

C07K 16/28, A61K 39/395

A1

(11) International Publication Number:

WO 96/12741

(43) International Publication Date:

2 May 1996 (02.05.96)

(21) International Application Number: PCT/EP95/04109

(22) International Filing Date: 20 October 1995 (20.10.95)

## (30) Priority Data:

9421463.2	25 October 1994 (25.10.94)	GB
9512480.6	20 June 1995 (20.06.95)	GB
9513415.1	30 June 1995 (30.06.95)	GB

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): BONNEFOY, Jean-Yves, Marcel, Paul [FR/CH]; The Glaxo Institute of Molecular Biology, 14, chemin des Aulx, Case postale 674, CH-1228 Plan-les-Ouates (CH).

(74) Agent: DAWSON, Hugh, B.; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

## Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: BINDING AGENTS TO CD23

## (57) Abstract

Binding agents to CD23 useful in the treatment of inflammatory, autoimmune or allergic diseases.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## BINDING AGENTS TO CD23

The present invention relates to particular binding agents which can be used for the treatment of inflammatory, autoimmune or allergic diseases.

CD23 (FC $\epsilon$ RII) is a type II molecule of the C-lectin family which also includes the lymphocyte homing receptor (MEL-14) and the endothelial leukocyte adhesion molecule-1 (ELAM-1). It is a low affinity receptor for IgE. In humans a variety of haematopoietic cell types express CD23 on their surface, including follicular dendritic cells, B cells, T cells and macrophages. CD23 molecules are also found in soluble forms in biological fluids. Soluble CD23 (sCD23) molecules are formed by proteolytic cleavage of transmembrane receptors. CD23 has pleiotropic activities including mediation of cell adhesion, regulation of IgE and histamine release, rescue of B cells from apoptosis and regulation of myeloid cell growth. These functional activities are mediated through the binding to specific ligands of cell-associated CD23, or sCD23, the latter acting in a cytokine-like manner (Conrad, D.H., *Annu Rev Immunol* 8, 623-645 1990); Delespesse, G., et al., *Adv Immunol* 49, 149-191 (1991); Bonnefoy, J.Y., et al., *Curr Opin Immunol* 5, 944-947 (1993)).

Increased expression of CD23 has been observed in a number of inflammatory diseases. CD23 has been identified in synovial biopsies from patients with chronic synovitis, and sCD23 can be measured at concentrations exceeding the normal range in the serum and synovial fluid of patients with rheumatoid arthritis (Bansal, A.S., Oliver, W., Marsh, M.N., Pumphrey, R.S., and Wilson, P.B., *Immunology* 79, 285-289 (1993); Hellen, E.A., Rowlands, D.C., Hansel, T.T., Kitas, G.D., and Crocker, J.J., *Clin Pathol* 44, 293-296 (1991); Chomarat, P., Brioloay, J., Banchereau, J., & Miossec, P., *Arthritis Rheum* 86, 234-242 (1993); Bansal, A., et al., *Clin Exp Immunol* 89, 452-455 (1992); Rezonzew, R., &

Newkirk, M.M., *Clin Immunol Immunopathol* 71, 156-163 (1994)). In addition, levels of serum sCD23 in rheumatoid arthritis patients are related to disease status and correlate with serum rheumatoid factor (Bansal, A.S., et al., *Clin Exp Rheumatol* 12, 281-285 (1994)). Pro-inflammatory cytokines appear to be particularly important in rheumatoid arthritis, and a central role for TNF- $\alpha$  and IL-1 $\beta$  in the destruction of arthritic joints has been postulated (Brennan, F.M., Chantry, D., Jackson, A., Maini, R., & Feldman, M., *Lancet* 2, 244-247 (1989); Brennan, F.M., Maini, R.M., & Feldman M., *Br J Rheumatol* 31, 293-298 (1992)).

It has also been postulated that CD23-CD21 interactions may play a role in the control of IgE production (Flores-Romo L. et al., *Science* 261 1038-1041 (1993); Aubry et al., *Nature* 358, 505-507 (1992)).

CD11b and CD11c are adhesion molecules that participate in many cell-cell and cell-matrix interactions. CD11b/CD18 and CD11c/CD18 (an association of CD11b and CD18 and of CD11c and CD18 respectively) have been reported to bind several ligands, including CD54, fibrinogen, factor X, LPS, Con A and zymosan (Springer, T.A, *Nature* 346, 425-434 (1990)). The role of these binding molecules is not however completely understood. CD11b/CD18 and CD11c/CD18 are also known as MAC-1 and p150, 95 respectively. They are members of the  $\beta_2$  integrin family (sometimes known as Leu-CAM, ie leucocyte cell adhesion molecules). This family also includes LFA-1 amongst its members (also known as CD11a/CD18).

EP 0205405 purports to disclose Mabs to lymphocyte cellular receptors for IgE (FC $\epsilon$ R) cross reacting with human immunoglobulin E binding factor (IgE-BF), and derivatives thereof.

WO 93/04173 purports to disclose a polypeptide which is capable of binding to one of FCEL (low affinity IgE receptor FCεRII) or FCEH (high affinity receptor FCεRI) but which is substantially incapable of binding to the other of FCEL or FCEH. Treatment of an allergic disorder is alleged with a FCEL or FCEH specific polypeptide (provided the FCEH specific polypeptide is incapable of crosslinking FCEH and inducing histamine release).

EP 0269728 purports to disclose Mabs to the human lymphocyte IgE receptor.

EP 0259585 purports to disclose Mabs recognising a surface receptor for IgE (FCεR) on human B lymphocytes.

WO 93/02108 purports to disclose primatised antibodies for therapeutic use.

The present inventors have surprisingly discovered that binding agents to CD23 can be of utility in the treatment or prophylaxis of various diseases and in particular in the treatment or prophylaxis of arthritis. Prior to the present invention no data has been presented which would support such a utility, despite the publication of a large number of papers in which CD23 has been discussed.

According to the present invention, there is provided a binding agent to CD23 for use in the treatment or prophylaxis of inflammatory, autoimmune or allergic diseases.

The binding agent may function by blocking the interaction between CD23 and a ligand which binds to it. *In vitro* assays e.g. radio-immune assays may be used to study such a blocking effect.

The binding agent may be in isolated form or as part of a pharmaceutical composition. Desirably it is in sterile form. Generally speaking a binding agent which is specific for CD23 is useful in the treatment/prophylaxis disclosed.

5 The present inventors have demonstrated that binding agents within the scope of the present invention work *in vivo* in treatment or prophylaxis of inflammatory or autoimmune diseases.

10 This demonstration is of great significance, given the fact that many of these diseases are difficult or impossible to treat effectively, despite long standing research into their nature and causes. This is particularly the case in respect of arthritis, which often affects people in middle age and can cause them to give up work prematurely. An effective treatment of arthritis has been a long standing goal of many research groups.

15 Preferred binding agents include antibodies, fragments thereof or artificial constructs comprising antibodies or fragments thereof or artificial constructs designed to mimic the binding of antibodies or fragments thereof. Such binding agents are discussed by Dougall *et al* in *Tibtech* 12, 372-379 (1994).

20 They include complete antibodies,  $F(ab')_2$  fragments, Fab fragments, Fv fragments, ScFv fragments, other fragments, CDR peptides and mimetics. These can be obtained/prepared by those skilled in the art. For example, enzyme digestion can be used to obtain  $F(ab')_2$  and Fab fragments (by subjecting an IgG to molecule to pepsin or papain cleavage respectively). References to "antibodies" in the following description should be taken to include all of the possibilities mentioned above.

25

Recombinant antibodies may be used. The antibodies may be humanized; or chimaerised.

5 A typical preparation of a humanised antibody in which the CDRs are derived from a different species than the framework of the antibody's variable domains is disclosed in EP-A-0239400. The CDRs may be derived from a rat or mouse monoclonal antibody. The framework of the variable domains, and the constant domains, of the altered antibody may be derived from a human antibody. Such a humanised antibody elicits a negligible immune response when administered to a human compared to the immune response mounted by a human against a rat or mouse antibody.

10 Alternatively, the antibody may be a chimaeric antibody, for instance of the type described in WO 86/01533.

15 A chimaeric antibody according to WO 86/01533 comprises an antigen binding region and a non-immunoglobulin region. The antigen binding region is an antibody light chain variable domain or heavy chain variable domain. Typically, the chimaeric antibody comprises both light and heavy chain variable domains. 20 The non-immunoglobulin region is fused at its C-terminus to the antigen binding region. The non-immunoglobulin region is typically a non-immunoglobulin protein and may be an enzyme region, a region derived from a protein having known binding specificity, from a protein toxin or indeed from any protein expressed by a gene. The two regions of the chimaeric antibody may be connected via a cleavable linker sequence. 25

The antibody may be a human IgG such as IgG1, IgG2, IgG3, IgG4; IgM; IgA; IgE or IgD carrying rat or mouse variable regions (chimaeric) or CDRs (humanised).

Primatizing techniques may also be used, such as those disclosed in WO93/02108.

5 As will be appreciated by those skilled in the art, where specific binding agents are described herein, derivatives of such agents can also be used. The term "derivative" includes variants of the agents described, having one or more amino acid substitutions, deletions or insertions relative to said agents, whilst still having the binding activity described. Preferably these derivatives have substantial amino acid sequence identity with the binding agents specified.

10 The degree of amino acid sequence identity can be calculated using a program such as "bestfit" (Smith and Waterman, Advances in Applied Mathematics, 482-489 (1981)) to find the best segment of similarity between any two sequences. The alignment is based on maximising the score achieved using a matrix of amino acid similarities, such as that described by Schwarz and Dayhof (1979) Atlas of Protein Sequence and Structure, Dayhof, M.O., Ed pp 353-358.

15 Preferably the degree of sequence identity is at least 50% and more preferably it is at least 75%. Sequence identities of at least 90% or of at least 95% are most preferred.

20 It will nevertheless be appreciated by the skilled person that high degrees of sequence identity are not necessarily required since various amino acids may often be substituted for other amino acids which have similar properties without substantially altering or adversely affecting certain properties of a protein. These are sometimes referred to as "conservative" amino acid changes. Thus the amino acids glycine, valine, leucine or isoleucine can often be substituted for one another (amino acids having aliphatic hydroxyl side chains). Other amino acids which can often be substituted for one another include:



phenylalanine, tyrosine and tryptophan (amino acids having aromatic side chains); lysine, arginine and histidine (amino acids having basic side chains); aspartate and glutamate (amino acids having acidic side chains); asparagine and glutamine (amino acids having amide side chains) and cysteine and methionine (amino acids having sulphur containing side chains). Thus the term "derivative" can also include a variant of an amino acid sequence comprising one or more such "conservative" changes relative to said sequence.

The present invention also includes fragments of the binding agents or of the present invention or of derivatives thereof which still have the binding activity described. Preferred fragments are at least ten amino acids long, but they may be longer (e.g. up to 50 or up to 100 amino acids long).

The binding agents of the present invention are believed to be useful in the treatment or prophylaxis of several human diseases including arthritis, lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, diabetes, uveitis, dermatitis, psoriasis, urticaria, nephrotic syndrome, glomerulonephritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Sjogren's syndrome, allergies, asthma, rhinitis, eczema, GVH, COPD, insulinitis, bronchitis (particularly chronic bronchitis) or diabetes (particularly Type 1 diabetes).

They may also be useful in studying the interactions between CD23 and various ligands e.g. between CD23 and CD21, between CD23 and CD11b, between CD23 and CD11c, between CD23 and a 70 to 85 KDa endothelial cell protein (which may be a 76, 80 or 85 KDa endothelial cell protein) or between CD23 and a 115 KDa endothelial protein (which is believed to be related to the 70 to 85 KDa endothelial protein). One or more of the above interactions are believed to occur, *in vivo*. Antibodies or other binding agents which are capable of blocking these interactions are particularly preferred since it is believed that they may be

especially suitable for reducing or alleviating cytokine mediated inflammatory effects. They may also be useful against B-cell malignancies such as chronic lymphocytic leukaemia, and hairy cell leukaemia.

- 5 Binding agents of the present invention are particularly applicable for use in the treatment or prophylaxis of rheumatoid arthritis. Without being bound by theory, the following possible explanations are put forward:-

10 In the rheumatoid arthritis inflamed synovium, macrophages express both CD23 and the  $\beta_2$  integrins CD11b and CD11c, allowing possible homotypic interactions to take place in this tissue. In addition, diffusion of soluble CD23 molecules through the synovium and their binding to the integrin ligands is also possible. Therefore, CD23-CD11b/CD11c interactions involving a positive activation loop could exist *in vivo*. If present in rheumatoid arthritis patients, it may explain some  
15 of the pathogenic mechanisms of disease exacerbation and chronicity, and would support the hypothesis that once localised to the joints, macrophages themselves can maintain and exacerbate inflammation via a pathway involving CD23 molecules,  $\beta_2$ -integrins CD11b and CD11c, as well as pro-inflammatory cytokines TNF- $\alpha$ , IL-1 $\beta$  and IL-6.

20 An alternative mechanism of action of anti CD23 therapy could involve the blocking of an IgE immune response.

25 In previously published work, it has been shown that *in vivo* treatment of rats with anti-CD23 antibody resulted in antigen-specific inhibition of IgE production, probably by blocking the CD23-CD21 interactions necessary for complete differentiation of IgE-committed B cells (Flores-Romo *et al.*, *Science* 261, 1038-1041 (1993)).

The present invention also includes binding agents to CD23 which block such a response.

Structurally, the CD21 protein is composed of an extracellular domain of 15  
(Moore *et al*, Molecular cloning of the cDNA encoding the Epstein Barr Virus C3d  
5 receptor (complement receptor type 2) of human B lymphocyte, *Proc Natl Acad Sci USA* **84**: 9194 (1987)) or 16 (Weis *et al*, Structure of the human B lymphocyte  
receptor for C3d and the Epstein Barr Virus and relatedness to other members of  
the family of C3/C4 binding proteins, *J Exp Med* **167**: 1047 (1988)) repetitive units  
10 of 60 to 75 amino acids, named short consensus repeats (SCRs), followed by a  
transmembrane domain (24 amino acids) and an intracytoplasmic region of 34  
amino acids. Using CD21 mutants bearing deletions of extracytoplasmic SCRs  
(Carel *et al*, Structural requirements for C3d,g/Epstein Barr Virus receptor  
(CR2/CD21) ligand binding, internalization, and viral infection *J Biol Chem* **265**:  
15 12293 (1990)), the present inventors have recently found that CD23 binds to  
SCRs 5-8 and 1-2 on CD21. The binding of CD23 to SCRs 5-8 is a lectin-like  
interaction, involving carbohydrates on Asn 295 and 370. In contrast, CD23  
binding to SCRs 1-2 is a protein-protein interaction (Aubry *et al*, CD23 interacts  
with a new functional extracytoplasmic domain involving N-linked  
20 oligosaccharides on CD21, *J Immunol* **152**: 5806 (1994)). The present inventors  
have now tested the effect of the other ligands of CD21 (EBV, C3d,g and IFN- $\alpha$ )  
on CD23 binding to CD21 and on the regulation of Ig production in the presence  
of IL-4. Only EBV particles and an EBV-derived peptide were able to inhibit  
CD23 binding to CD21. Moreover, the EBV-peptide selectively decreased IgE  
25 and IgG4 production and increased IgM production. These data indicate that  
CD23 binding to the EBV-binding site on CD21 selectively regulates human Ig  
production in the presence of IL-4.

Again without being bound by theory, it is believed that the present invention allows effective treatments to be achieved by suppressing the *de novo* synthesis of pro-inflammatory cytokines.

5 This contrasts with previous uses of antibodies simply to directly neutralise the cytokine molecules already present in inflamed tissues.

It should also be noted that there are speculative publications in the art listing large numbers of antibodies as well as large numbers of possible diseases which  
10 the antibodies are said to be useful in treating, but not providing any sound evidence or data for most of the possible combinations. One such publication is WO93/02108 which is primarily directed to the production of particular chimaeric antibodies.

15 The present invention is clearly distinguished from such publications by providing binding agents to particular molecules which are clearly indicated to be of utility in the treatment or prophylaxis of certain diseases in view of the data and explanations provided herein.

20 Binding agents of this invention are also of particular use in the treatment or prophylaxis of allergic diseases, including non-IgE mediated diseases. They may be used in the treatment and prophylaxis of ulcerative colitis. They may also be used in the treatment and prophylaxis of Crohn's disease.

25 The binding agents of the present invention may be used alone or in combination with immunosuppressive agents such as steroids, cyclosporin, or antibodies such as an anti-lymphocyte antibody or more preferably with a tolerance-inducing, anti-autoimmune or anti-inflammatory agent such as a CD4+T cell inhibiting agent e.g. an anti-CD4 antibody (preferably a blocking or non-depleting antibody), an

anti-CD8 antibody, a TNF antagonist e.g. an anti-TNF antibody or TNF inhibitor e.g. soluble TNF receptor, or agents such as NSAIDs.

5 The binding agent will usually be supplied as part of a sterile, pharmaceutically acceptable composition. This pharmaceutical composition may be in any suitable form, depending upon the desired method of administering it to a patient. It may be provided in unit dosage form and may be provided as part of a kit. Such a kit would normally (although not necessarily) include instructions for use.

10 Binding agent administrations are generally given parenterally, for example intravenously, intramuscularly or sub-cutaneously. The binding agents are generally given by injection or by infusion. For this purpose a binding agent is formulated in a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent. Any appropriate carrier or diluent may be used, for  
15 example isotonic saline solution. Stabilizers may be added such as a metal chelator to avoid copper-induced cleavage. A suitable chelator would be EDTA, DTPA or sodium citrate.

20 They may be given orally or nasally by means of a spray, especially for treatment of respiratory disorders.

They may be formulated as creams or ointments, especially for use in treating skin disorders.

25 They may be formulated as drops, or the like, for administration to the eye, for use in treating disorders such as vernal conjunctivitis.

For injectable solutions, excipients which may be used include, for example, water, alcohols, polyols, glycerine, and vegetable oils.

5 The pharmaceutical compositions may contain preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents or antioxidants. They may also contain other therapeutically active agents.

10 Suitable dosages of the substance of the present invention will vary, depending upon factors such as the disease or disorder to be treated, the route of administration and the age and weight of the individual to be treated. Without being bound by any particular dosages, it is believed that for instance for parenteral administration, a daily dosage of from 0.01 to 50 mg/kg of a binding agent of the present invention (usually present as part of a pharmaceutical composition as indicated above) may be suitable for treating a typical adult. More suitably the dose might be 0.05 to 10 mg/kg, such as 0.1 to 2 mg/kg.

15 This dosage may be repeated as often as appropriate. Typically administration may be 1 to 7 times a weeks. If side effects develop the amount and/or frequency of the dosage can be reduced.

20 A typical unit dose for incorporation into a pharmaceutical composition would thus be at least 1mg of binding agent, suitably 1 to 1000mg.

25 The present invention includes within its scope an assay for determining whether or not a particular agent which binds to CD23 may be useful in the treatment of an inflammatory, autoimmune or allergic disease comprising: determining whether or not the agent is capable of blocking the interaction between CD23 and CD11b, or the interaction between CD23 and CD11c, or the interaction between CD23 and CD21, or the interaction between CD23 and a 70 to 85 KDa (such as a 76 KDa, 85 KDa or 80 KDa) or a 115 KDa protein expressed on endothelial cells.

This assay can be used for screening compounds or molecules by using cell lines expressing the appropriate molecules. Preferably CD11b is used in these assays as CD11b/CD18 and CD11c is used as CD11c/CD18. CD11b/CD18 and CD11c/CD18 can be co-expressed on cell surface.

Any appropriate assay technique can be used, e.g. protein-non protein assays (e.g. assaying the interaction of proteins with chemicals or sugars), protein-protein assays or protein-cell assays.

The present invention will now be described by way of example only with reference to the accompanying drawings; wherein:

FIGURE 1 illustrates the effect of preventative treatment against arthritis on mice using an anti-CD23 antibody;

FIGURE 2 illustrates the effect of the treatment of mice with an anti-CD23 antibody in respect of established arthritis, where multiple treatments of the antibody are used;

FIGURE 3 illustrates the effect of the treatment of mice with an anti-CD23 antibody in respect of established arthritis where a single treatment is used;

FIGURES 4 a) and b) illustrate the effect of the treatment of mice with a monoclonal anti-CD23 antibody in respect of established arthritis where multiple treatments are used;

FIGURES 4 c) and d) illustrate the effect of the treatment of mice with  $F(ab')_2$  and Fab fragments of a monoclonal anti-CD23 antibody in respect of established arthritis where multiple treatments are used;

5                   FIGURE 5a illustrates CD23-liposomes binding to CD14 positive blood mononuclear cells;

10                   FIGURE 5b illustrates various CD23 affinity purified proteins on SDS-PAGE gels;

                  FIGURE 6 illustrates the percentage inhibition of CD23-liposome binding to activated blood monocytes obtained using certain monoclonal antibodies;

15                   FIGURE 7 illustrates the binding of CD23 liposomes to various transfected cells;

                  FIGURE 8 illustrates the effect of various substances on CD23-CD11b and CD23-CD11c interaction;

20                   FIGURE 9 illustrates the effects on nitrite production and oxidative burst in monocytes caused by CD23 binding to CD11b and CD11c; and

25                   FIGURE 10 illustrates that the binding of recombinant CD23 to CD11b and CD11c specifically increases cytokine production by monocytes.

### **EXAMPLES**



(In some of the following examples the terms "ip", "id" and "n" are used. These mean "intraperitoneal", "intradermal" and "number of animals" respectively.)

EXAMPLE 1 - Preventative Treatment of Mice against Arthritis using Anti-CD23

Antibody

Male DBA/1 mice (8-12 weeks old) were sedated with 0.1 ml of a 1:10 dilution of Fentanyl/Fluanisol 'Hypnorm' ip and injected intradermally at the base of the tail with 100 mg bovine type II collagen (CII) emulsified in Freund's complete adjuvant (Difco). On day 13 post-CII immunisation, test mice were treated with one single injection of rabbit anti-CD23 IgG purified by protein-A Sepharose (Bio-Processing, UK) (2 mg/mouse, ip) (n=16, ■—■). The purified anti-CD23 IgG contains 3-5% specific antibody.

A detailed description of its production is given in Flores-Romo L. *et al.*, *Science* **261** 1038-1041 (1993). Briefly, a rabbit polyclonal antibody was raised to a truncated form of human CD23 corresponding to amino acids 150 to 321 of full length CD23 [Kikutani *et al.*, *Cell* **47** 657 (1986)]. The truncated polypeptide was produced in *E. coli* and purified from a washed pellet of *E. coli* by ion-exchange and gel filtration. It had a molecular weight of 25kD and after purification was injected into a rabbit. The resultant antiserum tested positive in both an ELISA and a protein immunoblot with recombinant human CD23. An IgG fraction was then isolated by protein A-Sepharose affinity chromatography. Control animals received protein-A purified IgG from normal rabbit serum (2 mg/mouse) (n=17, ●- - - -●). Mice were inspected daily for development of clinical symptoms of arthritis. The severity of disease was scored on each paw using a scale from 0 = no symptoms to 3 = pronounced swelling, erythema and impairment of movement as described in Williams *et al.*, *Proc. Natl. Acad. Sci. USA* **89** 9784-9788 (1992); limb recruitment was assessed by counting the number of affected paws. Groups were compared by statistical analysis using

the two-tailed t-test in (a), and the non-parametric Mann-Whitney test in (b); \*0.05  $\geq p > 0.01$ , \*\*0.01  $\geq p > 0.005$ , \*\*\*0.005  $\geq p$ .

No difference in disease onset was observed (median day of onset + sem: 20 + 0.7 in test group and 20 0.5 in the control group) or incidence of disease (100% arthritic mice in both groups), demonstrating that treatment with anti-CD23 antibody had no effect on disease induction at the time of T-cell proliferation and IgG anti-collagen antibody induction. However, the overall clinical scores were lower in mice treated with anti-CD23 antibody (Fig. 1a). Most notable was the marked suppression of limb recruitment in the anti-CD23 treated group (Fig. 1b). These results indicate a strong influence of the treatment on the long-term progression of the disease.

#### EXAMPLE 2 - Treatment of Established Arthritis (multiple treatments)

Arthritis was induced as disclosed for Example 1 and mice were monitored daily for development of visible inflammation. Treatment was administered on first day of clinical inflammation (day 1) and two days later (day 3) on randomly divided three groups of mice. Test mice received protein-A purified anti-CD23 IgG (200  $\mu\text{g}/\text{injection}$ , n=6, ■ - - - - ■, 400  $\mu\text{g}/\text{injection}$ , n=8 ■ ——— ■, control mice received protein-A purified normal rabbit IgG (200  $\mu\text{g}/\text{injection}$ , n=15, ● - - - - ●). Severity of disease (Fig. 2a) was assessed as described in Example 1. Inflammation was assessed by the incremental swelling from day 1 of the first paw to become arthritic measured using callipers (Protest 2T, Kroeplin Langenmesstechnik). Groups were compared using the two-tailed t-test, \*0.05  $\geq p > 0.01$ , \*\*0.01  $\geq p > 0.005$ , \*\*\*0.0005  $\geq p$ .

Marked improvement in disease severity can be seen, which is dose related. The anti-inflammatory property of anti-CD23 IgG is clearly demonstrated by reduced paw swelling in the group of mice receiving antibody treatment.

EXAMPLE 3 - Treatment of Established Arthritis (single treatment)

Experiment design was similar to Example 2 with the exception that mice were treated only once, on day 1 of arthritis, with 2 mg/mouse of protein-A purified anti-CD23 IgG (n=10, ■——■) or purified normal rabbit IgG (n=10, ●- - -●). Clinical scores and limb recruitment was assessed as for Example 1.

The significant effect on limb recruitment obtained after one injection on day 1 demonstrates that in terms of joint recruitment a single injection administered when arthritis is already established is sufficient to protect against further disease progression (Fig. 3b).

EXAMPLE 4 - Treatment of Established Arthritis with Monoclonal Anti-CD23

Arthritic DBA/1 mice were obtained as described above for Example 1. On first sign of clinical disease mice were separated randomly in four groups and treated on days 1 and 3 with three doses of monoclonal antibody to CD23 (B3B4, kindly donated by Professor D. Conrad, Richmond, Virginia, USA and obtainable from Pharmingen. It is discussed in *J Immunol* 138: 1845-1851 (1987)); B3B4 25 µg/injection, n=4 ○·····○, B3B4 50 µg/injection, n=4; ■- - - -■, B3B4 100 µg/injection, n=5. ■——■). Control mice received PBS (n= 6 ●- - - -●). Clinical scores and increment in paw thickness from day 1 were assessed as described for Example 2.

Intraperitoneal injections of 50 µg of B3B4 monoclonal antibody were sufficient for effective therapy as shown by the significant decrease in clinical scores and the number of affected paws obtained using this treatment regimen. In contrast, the disease severity of mice treated with 25 µg monoclonal antibody did not improve the positive therapeutic effect obtained with 50 µg B3B4 monoclonal

antibody (Fig. 4). The dose-related anti-inflammatory effect of B3B4 administration is illustrated in Fig. 4b which shows that swelling of the arthritic paws did not increase from day 1 in the groups receiving ip injections of 50 or 100  $\mu$ g monoclonal antibody B3B4. Similarly to what was observed with the other clinical measurements, doses of 25  $\mu$ g monoclonal anti-CD23, administered after disease onset, were sub-therapeutic and the increments in paw swelling were similar to controls (Fig. 4b). Likewise, a significant reduction in severity of the established arthritis was obtained after treatment with 50  $\mu$ g affinity-purified polyclonal anti-CD23 IgG (data not shown).

The improvement in clinical severity following treatment with anti-CD23 antibody (both monoclonal and polyclonal) was confirmed by histological examination of the arthritic paws. Treated mice showed reduced severity of disease with less apparent destruction of cartilage and bone and a marked decrease in cellular infiltration of the sublining layer of the synovium. Moreover, the proportion of severely affected joints was significantly lower in anti-CD23 antibody treated animals in comparison to control mice (0 % vs 94 %), whereas the proportion of joints maintaining normal structure was significantly increased (80 % vs 0 %).

This is demonstrated in Table 1 below.

Table 1: Histopathology of paws: Mice were treated and joints processed as in Fig. 4. Histological preparations were scored as described in methodology.

Treatment (no of mice)	Normal (%)	Mild (%)	Moderate (%)	Severe (%)	Total number of joints examined
anti-CD23 (n=6)	80	8	12	0	59
controls (n=6)	0	0	6	94	69

This table shows a comparison of histological preparations in respect of joints taken from mice treated with anti-CD23 or from control mice. The mice had been treated as described above in relation to Fig 4.

Histopathology was assessed as follows:

The first limb to become arthritic was removed post-mortem, fixed in 10% (wt/vol) buffered formalin and decalcified in EDTA in buffered formalin (5.5%). The paws were then embedded in paraffin, sectioned and stained with haematoxylin and eosin. Histological preparations (3 sections/paw) were scored using the following criteria: mild + minimal synovitis, cartilage loss and bone erosions limited to discrete foci; moderate = synovitis and erosions present but joint architecture intact; severe = extensive synovitis and erosions with disruption of joint architecture. All the joints present in each section were assessed and the percentage presenting normal, mild, moderate or severe scores was determined. Inflammation was assessed by the increment in paw thickness relative to the thickness of the paw on the first day of treatment, measured using calipers (Protest 2T, Kroeplin Langenmesstechnik).

Further evidence to support specificity of this treatment was obtained by treating arthritic mice with Fab and F(ab')<sub>2</sub> fragments of B3B4 monoclonal antibody. Although less potent than the intact IgG molecule, Fab and F(ab')<sub>2</sub> fragments of B3B4 were still effective thus demonstrating that the Fc portion of the antibody is not compulsory for the activity (Table 2). Moreover, antibodies to CD72 and B220 molecules, both highly expressed on B lymphocytes, showed little to no therapeutic activity (Table 2). In addition comparison with antibodies to TNF- $\alpha$  (Williams *et al Proc Natl Acad Sci USA* 36: 9784-9788 (1992)) and CD5 (Plater-Zyberk *et al Clin Exp Immunol* 98: 442-447 (1994)) showed that in our experimental conditions, anti-CD23 antibody treatment was the most effective (Table 2).

**Table 2: Comparison in the response to different treatment regimen:** Mice were immunised with type II collagen and treated therapeutically on day 1 and 3 of clinical arthritis by i.p. injection of monoclonal antibodies. The decrease in clinical scores on day 5 was calculated as a percentage of the isotype control used in each experiment.

Mab	Clone	Treatment dose	Isotype	Decrease in clinical scores (%)
CD23	B3B4	50 $\mu$ g x 2	Rat IgG2a	74
		75 $\mu$ g x 2	Rat F(ab) <sub>2</sub>	52
		150 $\mu$ g x 2	Rat Fab	56
TNF- $\alpha$	1F3F3D4	50 $\mu$ g x 2	Rat IgM	63
CD5	TIB 104	200 $\mu$ g x 2	Rat IgG2a	30
B220	TIB 146	200 $\mu$ g x 2	Rat IgM	5
CD72	TIB 165	200 $\mu$ g x 2	Mouse IgG2b	0

Further data in respect of monoclonal antibodies and fragments thereof are provided in Figures 4c and 4d. Those data are based upon the following protocol:

- 5 Male 8-12 weeks old DBA/1 mice injected id with 100 µg bovine type II collagen emulsified in complete Freund's adjuvant.

On first sign of clinical disease ( $\pm$  3 weeks later) mice are injected ip with the following preparations of monoclonal antibodies, (injections on day 1 and day 3)

10

B3B4 whole IgG 2a	50 µg/injection ip n = 8
Fab of B3B4	150 µg/injection ip n = 6
F(ab') <sub>2</sub> of B3B4	75 µg/injection ip n = 7
M6 control IgG2a	50 µg/injection ip n = 7

15

Mice are inspected daily and severity of clinical disease of each paw is scored (max/paw = 3; max/mouse = 12). The results for the scoring of clinical disease are shown in Figure 4c.

- 20 The swelling of the first arthritic paw is followed using calipers. The results for the scoring of paw swelling are shown in Figure 4d.

Mice are killed on day 10 of arthritis, the first paw to become arthritic is sectioned, fixed and decalcified for histopathological examination.

25

Interaction between CD23 and CD11b and between CD23 and CD11c

Without wishing to be bound by theory, since it is not fully understood how anti-CD23 antibodies achieve the surprising results disclosed above, it is possible that

this may be due to the interaction of CD23 with CD11b and/or CD11c. Examples 5 to 10 and the accompanying Figures (see later) illustrate this.

In these Examples, full-length recombinant CD23 incorporated into fluorescent liposomes was shown to bind to COS cells transfected with cDNA encoding either CD11b/CD18 or CD11c/CD18 but not with transfectants expressing CD11a/CD18. The interaction between CD23-liposomes and CD11b/CD18 or CD11c/CD18-transfected COS cells was specifically inhibited by anti-CD11b or anti-CD11c, respectively, and by anti-CD23 monoclonal antibodies. The functional significance of this ligand pairing was demonstrated by triggering CD11b and CD11c on monocytes with either recombinant CD23 or anti-CD11b and anti-CD11c monoclonal antibodies to cause a marked increase in nitrite ( $\text{NO}_2^-$ ), oxidative products ( $\text{H}_2\text{O}_2$ ) and proinflammatory cytokines ( $\text{IL-1}\beta$ ,  $\text{IL-6}$  and  $\text{TNF}\alpha$ ). These CD23-mediated activities were decreased by Fab fragments of monoclonal antibodies to CD11b, CD11c and CD23. These results demonstrate that the surface adhesion molecules CD11b and CD11c are receptors for CD23 and that this novel ligand pairing regulates important activities of monocytes.

The following discussion explains briefly the experimental design and the rationale behind Examples 5 to 10 (which follow):-

Total blood mononuclear cells were incubated with recombinant full-length CD23 incorporated into fluorescent liposomes and analysed by flow cytometry (Pochon, S. *et al. J. Exp. Med.* 176, 389-398 (1992)). A fraction bound CD23-liposomes (Example 5, Fig. 5a) which was then shown by double staining to consist of CD14-positive cells (i.e. monocytes). To confirm that monocytes were able to bind CD23-liposomes, blood mononuclear cells were FACS-sorted into CD14-positive and CD14-negative populations (Example 5, Fig. 5a). CD23-liposomes were shown to bind only to the CD14-positive population (Example 5, Fig. 5a). Since monocytes were found to express neither membrane IgE nor CD21 (not



shown), the known ligands for CD23, it was investigated whether monocytes express a different receptor for CD23. Monocytes were lysed and cell extracts purified over an affinity column coupled with recombinant soluble CD23. SDS-PAGE and silver staining analysis of the eluted material revealed bands of around 80 and 160 kDa MW (Example 5, Fig. 5b). Antibodies identifying antigens within this range of MW and reported to be expressed on monocytes were tested by FACS for their capacity to inhibit CD23-liposome binding to monocytes (Example 6, Fig. 6). Anti-CD11b and anti-CD11c monoclonal antibodies both inhibited CD23-liposome binding to monocytes, with varying degrees of potency (Example 6, Fig. 6). Anti-CD13, anti-CD49d, anti-CD21 (not expressed on monocytes) and anti-CD11a (the third member of the  $\beta 2$  integrin family of adhesion molecules) had no significant effect (Example 6, Fig. 6). Antibodies against MHC Class I, Class II, CD14 and CD45, all of which highly expressed on monocytes, were also tested for their effect on CD23-liposome binding. None however had any effect (not shown). Anti-CD18 monoclonal antibody gave a partial inhibition of CD23 binding. This could be due either to steric hindrance or to the induction of a conformational change in the CD11b and CD11c molecules upon anti-CD18 Mab binding. The monocyte-derived proteins eluted from the CD23-affinity column were immunoreactive with anti-CD11c (Example 5, Fig. 5b) and anti-CD11c/CD18 antibodies (not shown).

To confirm that the  $\alpha$  chain of CD11b/CD18 and CD11c/CD11b were receptors for CD23, full-length cDNAs encoding CD11b and CD11c were transiently co-transfected with CD18 cDNA into COS cells. Transfectants expressing CD11b/CD18 and CD11c/CD18 were both shown to bind CD23-liposomes, in contrast to transfectants expressing CD11a/CD18 (Example 7, Fig. 7). This might be explained by the higher degree of homology between CD11b and CD11c when compared to their homology to CD11a. The specificity of the interaction was demonstrated by inhibiting CD23-liposome binding using anti-CD11b, anti-

CD11c and anti-CD23 monoclonal antibodies. The same results were obtained using BHK cells expressing CD11b/CD18 and CD11c/CD18 (not shown). As further proof of the specificity of the CD23 interaction, activated blood monocytes from a Leukocyte Adhesion Deficiency patient, lacking  $\beta 2$  integrin expression due  
5 a mutation in the gene encoding the  $\beta$  subunit were unable to bind CD23-liposomes (not shown). Together, these data demonstrate that CD23 interacts with CD11b and CD11c on normal human monocytes and on transfectants.

CD11b and CD11c are adhesion molecules that participate in many cell-cell and  
10 cell-matrix interactions. The examples show that CD11b/CD18 and CD11c/CD18 may exhibit an additional adhesive function by virtue of their ability to bind CD23. CD23 seems to identify an epitope close or identical to factor X as observed by the capacity of factor X to inhibit in a dose dependent manner CD23-liposome binding (Example 8, Fig. 8) without affecting surface expression of CD11b or  
15 CD11c on monocytes (not shown). None of the other ligands tested had any effect. CD23 may be acting as a C-type lectin in its interaction with CD11b and CD11c. EDTA decreases CD23 binding to monocytes (Example 8, Fig. 8) by chelation of  $\text{Ca}^{2+}$  which is necessary to CD23 binding and/or by chelation of the divalent cations which are necessary for the binding of ligands to CD11b and  
20 CD11c (Altieri, D.C. *J. Immunol.* **147**, 1891-1898 (1991)). CD23-CD11b/CD11c interaction seems to involve sugars, but not sialic acid, as observed by the capacity of tunicamycin, but not neuraminidase, to decrease CD23 binding to monocytes. CD23 bears extracellularly a triplet of amino acids (Asp, Gly, Arg) (Kikutani, H. *et al. Cell* **47**, 867-885 (1986)), which in the reverse orientation is a  
25 common recognition site for the integrin receptors. Therefore, the effect of a polyclonal antibody directed against this tripeptide was tested for its capacity to inhibit CD23 binding to monocytes. No inhibition was observed, confirming the absence of inhibition obtained with fibrinogen (Example 8, Fig. 8). IgE which is binding in the lectin domain of CD23, partially inhibits CD23 binding to monocytes.

(Example 8, Fig. 8). Those results indicate that CD23 would seem to be acting as a C-type lectin recognising partly sugar and protein structures, reminiscent of what has been observed for CD23 interaction with CD21 (Aubry, J-P. et al. *J. Immunol.* **152**, 5806-5813 (1994)).

5 To evaluate the functional significance of the interaction of CD23 with CD11b or CD11c, we investigated whether CD23-CD11b/CD11c interaction could trigger monocytes to release proinflammatory mediators such as nitric oxide,  $H_2O_2$  and cytokines. Triggering of adherence-activated normal monocytes using recombinant soluble CD23, anti-CD11b or anti-CD11c antibodies increased the generation of  $NO_2^-$  indicating the activation of the NO pathway (Moncada, S., Palmer, R.M.J. & Higgs, E.A. *Pharmacol. Rev.* **43**, 109-144 (1991)). The effect of CD23 on nitrite production was inhibited by Fab fragments of anti-CD23 monoclonal antibodies and by nitroarginine, a specific inhibitor of the NO synthase pathway (Example 9, Fig. 9a). The oxidative burst was also shown to be regulated through CD11b and CD11c since recombinant soluble CD23, anti-CD11b and anti-CD11c monoclonal antibodies all caused oxidation of hydroethidine to ethidium bromide in monocytes (Example 9, Fig. 9b). This confirms and extends the finding that anti-CD11b monoclonal antibodies induce an oxidative burst in monocytes (Trezzi, C., Schüep, B., Maly, F.E. & Jungi, T.W. *Brit. J. Haematol.* **77**, 16-24 (1991)). CD23 binding to CD11b and CD11c was associated with an early specific  $Ca^{2+}$  flux in blood monocytes (not shown).

15 Since activated macrophages are an important source of proinflammatory cytokines, we evaluated the effect of recombinant soluble CD23 and of anti-CD11b and anti-CD11c monoclonal antibodies on the production of such cytokines by monocytes. Recombinant soluble CD23, anti-CD11b and anti-CD11c monoclonal antibodies were potent stimulators of IL-1 $\beta$ , IL6 and TNF $\alpha$ . Again, the specificity of this induction was demonstrated by using Fab fragments of anti-CD11b, anti-CD11c and anti-CD23 monoclonal antibodies (Example 10,

Fig. 10). Interestingly, IL-1 and TNF $\alpha$  were potent inducers of CD23-liposome binding to monocytes (not shown), suggesting a potential cytokine autocrine loop through CD11b and CD11c stimulation and regulation.

5 EXAMPLE 5

a) CD23-liposomes bind to CD14-positive blood mononuclear cells (See Fig. 5a).

Blood mononuclear cells were stained with anti-CD14 monoclonal antibody (Becton Dickinson, Erembodegem, Belgium) followed by sheep FITC-conjugated F(ab')<sub>2</sub> antibodies to mouse IgG and IgM (Bioart, Meudon, France), both diluted in PBS, 0.5% BSA and 0.05% sodium azide prior to FACS-sorting (FACStar Plus, Becton Dickinson) into CD14-positive and CD14-negative cell populations. Separated cells were then stained with CD23-liposomes or control (glycophorin A)-liposomes diluted in 0.5% BSA, 0.1% sodium azide, 2 mM CaCl<sub>2</sub>, 140 mM NaCl, 20 mM Hepes, pH 7 and incubated for 2 h at 4°C (Pochon, S. et al., *J. Exp. Med.* 176 389-398 (1992)). After washes, cells (5,000 events/condition) were analysed by FACS.

b) Apparent molecular weight of CD23-affinity purified blood monocyte proteins and immunoreactivity with an anti-CD11c monoclonal antibody (See Fig. 5b).

Lysates of blood monocytes were affinity purified on a CD23-column, eluted proteins separated on SDS-PAGE gels and transferred onto nitrocellulose. Mr markers are shown on the left. The gel was silver stained (left lane). Filters were incubated with either an isotype matched antibody (middle lane) or with an anti-CD11c monoclonal antibody (BU-15, right lane), then with horseradish peroxidase-conjugated goat anti-mouse antibody (Kpl; Gaithersburg, Massachusetts).

25 EXAMPLE 6

Anti-CD11b and anti-CD11c monoclonal antibodies decrease CD23-liposome binding to activated blood monocytes (See Fig. 6).

Monocytes were enriched from mononuclear cells by Ficoll and overnight adherence to plastic in RPMI 1640 (Seromed, Berlin, Germany) supplemented with 2 mM glutamine and 10% heat-inactivated FCS (Flow Laboratories, Irvine, Scotland). Activated monocytes were then incubated with CD23-liposomes in the presence of different monoclonal antibodies ( $\alpha$ CD) or isotype-matched controls (CTRL) (Becton Dickinson), all tested at 10  $\mu$ g/ml. Anti-CD11a monoclonal antibodies 25.3 and B-B15 were obtained from Immunotech (Luminy, France) and Serotec (Oxford, UK), respectively. Anti-CD11b monoclonal antibody 44 was from Serotec, mon.gran 1 was from Janssen (Beerse, Belgium), Leu-15 was from Becton Dickinson (Erembodegem, Belgium) and (Bear-1) was from Sera-Lab Ltd (Sussex, GB). Anti-CD11c monoclonal antibody 3.9 was from Serotec, SL9 was from Sera-Lab and BU-15 was from The Binding Site (Birmingham, UK). Anti-CD13 (SJ1D1), anti-CD18 (BL5), anti-CD23 (mAb25) and anti-CD49d (HP2.1) monoclonal antibodies were from Immunotech. Anti-CD21 monoclonal antibody BL13 was from Immunotech, OKB7 from Ortho and BU-33 was obtained from Dr. MacLennan (Birmingham University, UK), HB-5 from ATCC, OKB7 from Ortho Diagnostics System Inc (Raritan, NJ). Anti-CD14, anti-CD3, anti-CD16 and anti-CD20 monoclonal antibodies were from Becton-Dickinson. Cells were analysed by FACS and mean fluorescence intensity (MFI) measured. Data of a representative experiment are presented. MFI of cells stained with control-liposomes was 6.5 and with CD23-liposomes was 84.5. Percentage inhibition using arithmetic linear MFI values is calculated according to the following formula:

$$\% \text{ inhibition} = \text{MFI} \frac{[(\text{CD23-lipo})] - [(\text{CD23-lipo}) + \text{Mab}]}{(\text{CD23-lipo})} \times 100$$

5

EXAMPLE 7

CD23-liposomes bind to  $\alpha$  chains of CD11b/CD18 and CD11c/CD18 on recombinant transfectants (See Fig. 7). cDNAs coding for CD11a (Corbi, A.L., Miller, L.J., O'Connor, K., Larson, R.S. & Springer, T.A. *EMBO J.* **6**, 4023-4028 (1987)) was recloned in pCDNA1 (Invitrogen, San Diego, CA). cDNA for CD11b (Corbi, A.L., Kishimoto, T.K., Miller, L.J. & Springer, T.A. *J. Biol. Chem.* **263**, 12403-12411 (1988)) and CD18 (Kishimoto, T.K., O'Connor, K., Lee, A., Roberts, T.M. & Springer, T.A. *Cell* **48**, 681-690 (1987)) were recloned in pCDM8 (Seed, B., *Nature* **329** 840-842 (1987)). 20  $\mu$ g aliquots of DNA were transfected in COS-7 cells (ATCC) by electroporation (260 V, 960  $\mu$ FD) using a Gene Pulser device (Bio-Rad, Richmond, CA) and 0.4 cm cuvettes in 20 mM Hepes pH 7.4, 150 mM NaCl. Co-transfections of CD11a, b or c with CD18 were performed in order to get expression of the  $\beta$ 2 integrins at the cell surface. Controls were done with single chain transfections. 48 h after transfection, COS cells were stained with anti-CD11a, anti-CD11b and anti-CD11c monoclonal antibodies or isotype-matched monoclonal antibodies (control) followed by FITC-labelled sheep anti-mouse antibody. Between 10 to 15% of the cells were shown to express CD11a, b, c or CD18 by staining with the respective monoclonal antibodies. Prior to staining with CD23-liposomes, CD18-positive transfected COS cells were then FACS-sorted in order to increase the percentage of cells expressing  $\beta$ 2 integrins. CD11a/CD18, CD11b/CD18 and CD11c/CD18 transfectants were then incubated with CD23-liposomes (trace 2) or control (glycophorin A)-liposomes (trace 1). The specificity of CD23 interaction with CD11b and CD11c was demonstrated by inhibition of CD23-liposome binding to CD11b/CD18 and CD11c/CD18

transfectants using anti-CD11b (trace 4), anti-CD23 (trace 5) and anti-CD11c (trace 6) monoclonal antibodies, respectively. No binding of CD23-liposomes was observed on CD11a/CD18 transfectants and no effect of anti-CD11a monoclonal antibody was found (trace 3).

5

#### EXAMPLE 8

Structural characterisation of CD23-CD11b, CD11c interaction (See Fig. 8).

(a) Involvement of sugars and divalent cations.

10 Purified activated blood monocytes were treated or not with tunicamycin (10 µg/ml) for 48 h or with neuraminidase (0.1 U/ml; both from Boehringer Mannheim, Mannheim, Germany) for 45 min. Cells were then incubated with CD23-liposomes or control-liposomes in the absence or presence of EDTA (5 mM; top left panel), Ca<sup>2+</sup> or Mn<sup>2+</sup> (1 to 10 mM; top right panel).

15 (b) Factor X does inhibit CD23 binding to monocytes. Purified activated blood monocytes were incubated with CD23-liposomes in absence or presence of factor X (0.1 to 10 U/ml; Sigma) (bottom left panel), fibrinogen (50 µg/ml; Sigma), purified recombinant ICAM-1 (produced in our laboratory), LPS (1 µg/ml; Sigma), human serum opsonised-zymosan (1 mg/ml; Sigma), IgE (50 µg/ml; The Binding Site, Birmingham) or polyclonal antibody to RGD peptide (1/500, ATCC) (bottom right panel). Cells were analysed by FACS and MFI measured. Percentage inhibition was calculated as for Example 6.

20

#### EXAMPLE 9

25 Recombinant CD23 by binding to CD11b and CD11c specifically increases a, the nitrite product and b, the oxidative burst by monocytes.

Monocytes were incubated a, for 4 days at 37°C or b, overnight in the absence or presence of recombinant soluble CD23 (Graber P. *et al.*, *J. Immunol. Methods* **149** 215-226 (1992)) (50 ng/ml), anti-CD11a (clone 25.3), anti-CD11b (clone 44), anti-CD11c (clone BU-15) monoclonal antibodies (all at 10 µg/ml).

To assess the amount of NO produced (which is shown in Fig. 9a), the culture supernatants were assayed for the stable end products of NO, NO<sub>2</sub><sup>-</sup> and NO<sub>3</sub><sup>-</sup> according to Green *et al.*, *Annu. Rev. Immunol.* **2** 199-218 (1984). The specificity of CD23-mediated increase of NO<sub>2</sub><sup>-</sup> production was demonstrated by inhibition of NO<sub>2</sub><sup>-</sup> production by Fab fragments of anti-CD23 monoclonal antibodies (mab25) (tested at 10 µg/ml) and by inhibition with nitroarginine (N-Arg at 1 mM) (Sigma).

Activated monocytes were incubated with hydroethidine (Molecular probes, Eugene, OR) (0.3 µg/ml) for 30 min at 37°C (Rothe G. *et al.*, *J. Leukoc. Biol.* **47** 440-448 (1990)) and analysed by FACS. Percentage increase in red fluorescence of stimulated monocytes is shown in comparison to untreated monocytes (See Fig. 9b). Monocytes which had undergone an oxidative burst shown an increase of red fluorescence signals compared to untreated monocytes reflecting oxidation of hydroethidine to ethidium bromide (Lacal P.M. *et al.*, *Biochem. J.* **268** 707-712 (1990)). MFI values of monocytes alone were 159+/-10. Mean+/-SD values of 6 experiments are presented. Con A, which is known to induce a respiratory burst in monocytes, was used as a positive control. The specificity of the CD23 interaction with CD11b and CD11c was demonstrated by inhibition of CD23-mediated increase of H<sub>2</sub>O<sub>2</sub> production by Fab fragments of anti-CD11b (clone 44), anti-CD11c (clone BU-15) and anti-CD23 (mAb25) monoclonal antibodies (tested at 10 µg/ml).

#### EXAMPLE 10

Binding of recombinant CD23 to CD11b and CD11c specifically increases cytokine production by monocytes (See Fig. 10).

Monocytes were incubated overnight at 37°C in the absence or presence of recombinant soluble CD23 (Graber P. *et al.*, *J. Immunol. Methods* **149** 215-226 (1992)) (50 ng/ml), anti-CD11a (clone 25.3), anti-CD11b (clone 44), anti-CD11c



(clone BU-15), anti-CD23 (mAb 25 - this antibody is available from Immunotech. It is discussed in published European Patent Application EP-A-0269728) monoclonal antibodies, Con A (Sigma) (all at 10 µg/ml), LPS (1 ng/ml) (Sigma) or PMA (5 ng/ml) (Calbiochem, La Jolla, CA). Cytokines were measured in the culture supernatant by specific ELISA. The ELISA's limit of sensitivity is 0.05 ng/ml for IL-1β (Femua *et al.*, *J. Immunol. Methods* **114** 41-48 (1988)) 0.01 ng/ml for TNFα (Medgenix, Biotechnie, Rungis, F) and <0.01 ng/ml for IL-6 (Manie *et al.*, *Eur. Cytokine Netw.* **4** 51-56 (1993)). The specificity of CD23 interaction with CD11b and CD11c was demonstrated by inhibition of CD23-mediated increase of cytokine production by Fab fragments of anti-CD11b (clone 4), anti-CD11c (clone BU-15) and anti-CD23 (mAb25) monoclonal antibodies (tested at 10 µg/ml). Mean±SD values of 4 experiments are presented.

#### EXAMPLE 11

Monoclonal antibodies to recombinant *E. coli* derived soluble human CD23 (25 kD, amino acids 150-321) were raised in mice, by standard procedures except using lymph nodes not spleen cells. These blocked the activities of human CD23 *in vitro*.

#### EXAMPLE 12

##### Ulcerative colitis

3 tamarin monkeys were dosed with anti-CD23 Mab without adverse effects, resulting in an improvement in subjective faecal score.

The dosage was 1mg every 4 days by intramuscular injection.

#### EXAMPLE 13

No toxic effects were observed in any tests reported here.

CLAIMS

- 5 1. A binding agent to CD23 for use in the treatment or prophylaxis of inflammatory, autoimmune or allergic diseases.
2. A binding agent according to claim 1, wherein the binding agent is an antibody, a fragment thereof, an artificial construct comprising an antibody or comprising a fragment thereof, a mimetic, or a derivative of any of these binding agents.
- 10 3. A binding agent according to claim 1 or 2 which is a humanised or chimaerised antibody.
- 15 4. A binding agent according to any preceding claim which blocks interaction between CD23 and ligands which bind to it *in vivo*.
- 20 5. A binding agent according to any preceding claim for use in the treatment of arthritis, lupus erythematosus, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, diabetes, uveitis, dermatitis, psoriasis, urticaria, nephrotic syndrome, glomerulonephritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Sjogren's syndrome, allergies, asthma, eczema, GVH, COPD, bronchitis, insulinitis, rhinitis or diabetes.
- 25 6. A binding agent according to any of claims 1 to 4 for use in the treatment of arthritis, allergies, ulcerative colitis or Crohn's disease.
7. A binding agent according to claims 6, for use in the treatment of rheumatoid arthritis.

8. The use of a binding agent to CD23 for the manufacture of a medicament for the treatment of arthritis, lupus erythematosus, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, diabetes, uveitis, dermatitis, psoriasis, urticaria, nephrotic syndrome, glomerulonephritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Sjogren's syndrome, allergies, asthma, eczema, GVH, COPD, bronchitis, insulinitis, rhinitis or diabetes.

9. The use of claim 8, for the treatment of arthritis, allergies, ulcerative colitis or Crohn's disease.

10. The use of claim 9 for the treatment of rheumatoid arthritis.

11. A pharmaceutical composition comprising a binding agent to CD23 and a pharmaceutically acceptable carrier.

12. A composition according to claim 11, containing a unit dose of binding agent of at least 1mg.

13. A pharmaceutical composition according to claim 11 or 12 wherein the binding agent is an antibody.

14. A pharmaceutical composition according to claim 13 wherein the antibody is a humanised or a chimaerised antibody.

15. A pharmaceutical composition according to claim 11 substantially as hereinbefore described.

16 A binding agent, use or pharmaceutical composition according to any one of the preceding claims, wherein the binding agent is in combination with an immunosuppressive, tolerance-inducing, anti-autoimmune or anti-inflammatory agent.

5

17. A binding agent, use or pharmaceutical composition according to claim 16 wherein the binding agent is in combination with a CD4+T cell inhibiting agent or a TNF antagonist.

10

18. A binding agent, use or pharmaceutical composition according to claim 17 wherein the binding agent is in combination with an anti-CD4 antibody.

19. A binding agent according to claim 1 substantially as hereinbefore described.

15

20. A method of treating an inflammatory, autoimmune disease or an allergic disease comprising administering a pharmaceutically effective amount of a binding agent to CD23 to a patient.

1/10 FIG.1a





FIG.1b



2 / 10

FIG. 2a





FIG. 2b



3 / 10

FIG. 3a





FIG. 3b



4 / 10

FIG. 4a





FIG. 4b





5 / 10

FIG. 5a






FIG. 5b



6 / 10

FIG. 6



7 / 10




FIG. 7

8 / 10




FIG. 8

9 / 10

FIG. 9a






FIG. 9b



10/10

FIG. 10



# INTERNATIONAL SEARCH REPORT

International Application No  
T/EP 95/04109

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07K16/28 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 205 405 (CIBA-GEIGY AG) 17 December 1986  see the whole document ---	1,2,4-6, 8,9,11, 13,15, 19,20
X	THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 102, no. 3, March 1994 NEW YORK, NY, USA, pages 321-327, N. ISHII ET AL. 'DNFB contact sensitivity (CS) in BALB/c and C3H/He mice: Requirement for early-occurring, early-acting, antigen-specific, CS-initiating cells with an unusual phenotype....etc.' see the whole document ---	1,2,4-6, 8,9,11, 13,15, 19,20

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

22 January 1996

Date of mailing of the international search report

21.03.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (- 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (- 31-70) 340-3016

Authorized officer

Nooij, F

# INTERNATIONAL SEARCH REPORT

International Application No  
PC./EP 95/04109

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCIENCE, vol. 261, 20 August 1993 WASHINGTON, DC, USA, pages 1038-1041, L. FLORES-ROMO ET AL. 'Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23.' cited in the application see the whole document ---	1,2,4-6, 8,9,11, 13,15, 19,20
X	EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, no. 7, July 1993 WEINHEIM, GERMANY, pages 1739-1742, B. HEYMAN ET AL. 'In vivo enhancement of the specific antibody response via the low-affinity receptor for IgE.' see the whole document ---	1,2,4-6, 8,9,11, 13,15, 19,20
A	THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 176, no. 2, 1 August 1992 NEW YORK, NY, USA, pages 389-397, S. POCHON ET AL. 'Demonstration of a second ligand for the low affinity receptor for immunoglobulin E (CD23) using recombinant CD23 reconstituted into fluorescent liposomes.' cited in the application see abstract see page 390, left column, line 19 - line 31 see page 391, right column, line 12 - line 25 ---	1,2, 4-13,15, 19,20
A	WO,A,93 02108 (IDEC PHARMACEUTICALS CORPORATION) 4 February 1993 cited in the application see claims ---	1-20
A	WO,A,87 07302 (LABORATOIRES UNICET) 3 December 1987 see claims ---	1-20
A	THE JOURNAL OF IMMUNOLOGY, vol. 138, no. 6, 15 March 1987 BALTIMORE, MD, USA, pages 1845-1851, M. RAO ET AL. 'Characterization of a monoclonal antibody directed against the murine B lymphocyte receptor for IgE.' cited in the application see abstract ---	1-20

-/--



# INTERNATIONAL SEARCH REPORT

Inventor's National Application No  
PLT/EP 95/04109

## C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

A THE JOURNAL OF IMMUNOLOGY,  
vol. 138, no. 9, 1 May 1987 BALTIMORE, MD,  
USA,  
pages 2970-2978,  
J-Y. BONNEFOY ET AL. 'Production and  
characterization of a monoclonal antibody  
specific for the human lymphocyte low  
affinity receptor for IgE: CD23 is a low  
affinity receptor for IgE.'  
see abstract

1-20

P,X NATURE MEDICINE, ---  
vol. 1, no. 8, August 1995 NEW YORK, NY,  
USA,  
pages 781-785,  
C. PLATER-ZYBERK ET AL. 'Marked  
amelioration of established  
collagen-induced arthritis by treatment  
with antibodies to CD23 in vivo.'  
see the whole document

1,2,  
4-13,15,  
19,20

P,X IMMUNITY, ---  
vol. 3, no. 1, July 1995 USA,  
pages 119-125,  
S. LECOANET-HENCHOZ ET AL. 'CD23  
regulates monocyte activation through a  
novel interaction with the adhesion  
molecules CD11b-CD18 and CD11c-CD18.'  
see page 123, right column, line 3 - line  
14

1,2,  
4-13,15,  
19,20

P,X EUROPEAN JOURNAL OF IMMUNOLOGY, ---  
vol. 24, no. 12, December 1994 WEINHEIM,  
GERMANY,  
pages 2982-2986,  
I. GROSJEAN ET AL. 'CD23/CD21 interaction  
is required for presentation of soluble  
protein antigen by lymphoblastoid B cell  
lines to specific CD4+ T cell clones.'  
see the whole document

1,2,5-9,  
11,13,  
15,19,20

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 95/04109

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 20  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 20 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition/compound.

2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 95/04109

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-205405	17-12-86	DE-D- 3689734 DE-T- 3689734 IE-B- 61820 JP-B- 7107079 JP-A- 61289100 US-A- 4946788	28-04-94 21-07-94 30-11-94 15-11-95 19-12-86 07-08-90
WO-A-9302108	04-02-93	AP-A- 307 AU-B- 2425592 BG-A- 98411 BR-A- 9206313 CA-A- 2114015 CZ-A- 9400149 EP-A- 0605442 FI-A- 940336 HU-A- 70272 JP-T- 6509708 NO-A- 940219 NZ-A- 243706 OA-A- 9879 PT-A- 100735 SK-A- 8894	31-01-94 23-02-93 28-02-95 11-04-95 04-02-93 13-07-94 13-07-94 10-03-94 28-09-95 02-11-94 25-03-94 26-08-94 15-09-94 29-10-93 07-09-94
WO-A-8707302	03-12-87	FR-A- 2599513 DE-A- 3775182 EP-A, B 0269728 JP-T- 1500564	04-12-87 23-01-92 08-06-88 01-03-89